6CM
VKTX icon

683 Capital Management’s Viking Therapeutics VKTX Stock Holding History

683 Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.95M Sell
60,000
-76,500
-56% -$2.46M 0.1% 114
2025
Q4 		$4.8M Buy
136,500
+36,500
+37% +$1.29M 0.21% 87
2025
Q3 		$2.63M Buy
+100,000
New +$2.98M 0.14% 103

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

683 Capital Management's VKTX Position: Q1 2026 in Review

683 Capital Management reduced its Viking Therapeutics (VKTX) stake by 29% in Q1 2026, selling an estimated $1.67M and leaving 130,000 shares worth $4.23M. The position accounts for 0.22% of the portfolio, ranked #79.

683 Capital Management first reported a position in VKTX in Q4 2022 and has held it in 14 quarters since. The position peaked at $29.1M in Q1 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • 683 Capital Management held 130,000 shares of Viking Therapeutics worth $4.23M as of Q1 2026.
  • 683 Capital Management sold 52,000 Viking Therapeutics shares in Q1 2026, an estimated $1.67M.
  • Viking Therapeutics made up 0.22% of 683 Capital Management's portfolio in Q1 2026, its #79 holding.
  • 683 Capital Management first reported a position in Viking Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • 683 Capital Management's Viking Therapeutics position peaked at $29.1M in Q1 2024.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.